Valuation : Alligator Bioscience AB

Market Cap 15.07M 1.57M 1.35M 1.27M 1.16M 2.17M 149M 2.18M 5.83M 76.1M 5.89M 5.77M 241M P/E 2026 *
-
P/E 2027 * -
Enterprise Value 15.07M 1.57M 1.35M 1.27M 1.16M 2.17M 149M 2.18M 5.83M 76.1M 5.89M 5.77M 241M EV / Sales 2026 *
2.56x
EV / Sales 2027 * 0.3x
Free-Float
83.58%
Yield 2026 *
-
Yield 2027 * -
1 day-99.99%
1 week+1,143.80%
Current month+855.06%
1 month+770.83%
3 months+65.75%
6 months+70.87%
Current year-0.28%
1 week 0.02
Extreme 0.0227
0.32
1 month 0.02
Extreme 0.0227
0.32
Current year 0.02
Extreme 0.0227
0.42
1 year 0.02
Extreme 0.0227
5.42
3 years 0.02
Extreme 0.0227
1,508
5 years 0.02
Extreme 0.0227
3,509.77
10 years 0.02
Extreme 0.0227
34,002.21
Manager TitleAgeSince
Chief Executive Officer 55 2021-05-31
Director of Finance/CFO 61 2024-08-11
Chief Tech/Sci/R&D Officer - 2025-03-31
Director TitleAgeSince
Chairman 55 -
Director/Board Member 64 2021-05-31
Director/Board Member 68 2022-05-08
Change 5-day change 1-year change 3-year change Capi.($)
-99.99%+1,143.80% - - 1.57M
+0.63%-6.91%-2.66%+11.21% 46.38B
+0.17%-0.74%+407.28%+546.58% 44.51B
-0.86%-2.60%+35.51%+20.35% 42.3B
-0.14%-2.98%-0.04%+82.21% 39.91B
0.00%-1.72%+13.42%+42.33% 32.79B
-3.44%-2.43% - - 17.13B
-0.78%-1.13%+20.74%+116.26% 16.36B
+0.42%-3.08%+13.12%+31.41% 14.31B
-0.86%-4.60%+76.86%+39.36% 13.29B
Average -10.70%-2.88%+70.53%+111.21% 29.66B
Weighted average by Cap. -0.62%-3.04%+86.03%+133.10%

Financials

2026 *2027 *
Net sales 5.9M 614K 529K 498K 454K 849K 58.46M 852K 2.28M 29.78M 2.31M 2.26M 94.36M 49.7M 5.18M 4.45M 4.19M 3.82M 7.15M 492M 7.18M 19.21M 251M 19.43M 19.01M 795M
Net income -15.2M -1.58M -1.36M -1.28M -1.17M -2.19M -151M -2.2M -5.87M -76.73M -5.94M -5.81M -243M 28.9M 3.01M 2.59M 2.44M 2.22M 4.16M 286M 4.17M 11.17M 146M 11.3M 11.06M 462M
Net Debt - -
Logo Alligator Bioscience AB
Alligator Bioscience AB is a Sweden-based biotechnology Company that develops antibody-based drugs for cancer treatment. The Company specializes in the development of tumor-targeted immunotherapies, in particular agonist mono- and bispecific antibodies, and is active in the early stages of drug development, from concept to phase II clinical trials. Alligator’s pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its technology platform, Neo-X-Prime, with MacroGenics Inc. and drug candidates based on the RUBY bispecific platform with Orion Corporation. Its licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. The Company operates domestically.
Employees
11
Date Price Change Volume
26-09-09 SEK 0.0227 -12.69% 29,144
26-09-08 SEK 0.0260 +2.77% 40,000
26-09-04 SEK 0.0253 -2.32% 4
26-09-03 SEK 0.0259 +0.39% 90,000
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B

Annual profits - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!